Skip to content
Laurus Labs logo

Laurus Labs

LAURUSLABS NSE
₹2,323.80 +0.80 (+0.03%)
P/E
114.81
View as Markdown
MCP
Close 4 Nov 2026 ₹2,323.80 +1,344.00 +137% 1Y
Start ₹979.80

Key Fundamentals

LargecapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
17.80%
Debt to Equity
0.48
EPS (TTM)
₹20.24
Book Value
₹112.17
Market Cap
—
P/E (TTM)
114.81
P/B
20.72
ROE
18.30%
Dividend Yield
0.04%
EBITDA
₹1,833 Cr
52W High
₹2,441.90
52W Low
₹917.95
Day Range
₹2,285.60 – ₹2,343.90
Volume
32,19,107

Peer Comparison

Healthcare › Pharmaceuticals

Laurus Labs peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs (this company)
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Median 7 companies₹1,773.4038.81₹1,25,446 Cr4.770.58%16.50%17.80%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

54 Average

Data confidence 100/100

Category scores

Quality
69
Strong
Returns, margins, earnings quality 22% weight
Valuation
21
Poor
Cheap vs sector & own history 24% weight
Growth
70
Strong
Sales & profit trajectory 9% weight
Financial Health
48
Average
Solvency, leverage, coverage 9% weight
Momentum
98
Strong
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 19.0%

Weaknesses

4
  • Stock is trading at 21.1 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1513
OscillatorsBullish153
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
68.96
Neutral
MACD (12,26,9)
92.83
Bullish
SMA (50)
2,013.18
Bullish
SMA (200)
1,467.82
Bullish

As of

Analyst Rating

Based on 12 analysts
BUY50%

6 of 12 analysts rate Buy, 3 Hold, 3 Sell.

As of

BUY
6
50%
HOLD
3
25%
SELL
3
25%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+14.38%
5Y+7.19%
3Y+4.09%
1Y+22.67%
TTM+22.60%

Net profit

Net profit growth by window
10Y+20.84%
5Y−1.99%
3Y+3.92%
1Y+148.60%
TTM+114.57%

Operating cash flow

Operating cash flow growth by window
10Y+24.47%
5Y+17.25%
3Y+17.78%
1Y+169.77%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+5.84 pp
5Y−6.04 pp
3Y−0.15 pp
1Y+7.20 pp
TTM+6.62 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,905 Cr
Mar 2018₹2,056 Cr
Mar 2019₹2,292 Cr
Mar 2020₹2,832 Cr
Mar 2021₹4,814 Cr
Mar 2022₹4,936 Cr
Mar 2023₹6,041 Cr
Mar 2024₹5,041 Cr
Mar 2025₹5,554 Cr
Mar 2026₹6,813 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹190 Cr
Mar 2018₹168 Cr
Mar 2019₹94.00 Cr
Mar 2020₹255 Cr
Mar 2021₹984 Cr
Mar 2022₹832 Cr
Mar 2023₹793 Cr
Mar 2024₹162 Cr
Mar 2025₹358 Cr
Mar 2026₹890 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹615 Cr −19.4% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 2 Nov 2026
AI opinion · based on fundamentals
Risk high

Laurus Labs trades at ₹2,348 as of 2026-11-02 with a market cap of ₹1,28,919 Cr. The stock has rallied sharply with a 1-year CAGR of 136%, supported by a TTM profit growth of 115% and TTM sales growth of 23%, but trades at a PE of 116x and 21x book value, reflecting stretched valuations relative to its longer-term growth track record.

Bull Case 8
  • TTM profit growth of 115% signals a strong earnings recovery, well above the 10-year compounded profit growth of 21%
  • TTM sales growth of 23% marks a meaningful acceleration compared to the 3-year compounded sales growth of 4%
  • ROE improved to 18% in the last year, up from the 3-year average of 10%, indicating improving capital efficiency
  • ROCE stands at 19.67% as of 2026-11-02, suggesting the company generates reasonable returns on total capital employed
  • Debt-to-equity ratio of 0.48 reflects a manageable leverage position for a capital-intensive healthcare company
  • 10-year compounded profit growth of 21% and 10-year compounded sales growth of 14% demonstrate a long-term structural growth trajectory
  • The company has maintained a healthy dividend payout of 19.0%, providing some capital return to shareholders
  • Stock price CAGR of 72% over 3 years and 27% over 5 years indicates sustained investor confidence over medium to long horizons
Bear Case 7
  • Stock trades at 21.1 times book value, far above typical healthcare sector multiples, pricing in significant future growth
  • 5-year compounded profit growth is negative at -2%, indicating the recent earnings surge follows a prolonged period of profit decline
  • 5-year compounded sales growth of just 7% reflects sluggish top-line expansion over the medium term despite the recent uptick
  • 3-year average ROE of only 10% suggests the elevated last-year ROE of 18% may not be sustainable
  • Dividend yield of just 0.04% as of 2026-11-02 offers negligible income support at the current price level
  • The company might be capitalizing interest costs, which could flatter reported profitability and understate true operating expenses
  • The stock is trading near its 52-week high of ₹2,441.90 (just 4% below), with the 52-week low at ₹917.95, implying the price has more than doubled in a year and may be vulnerable to mean reversion

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Laurus Labs is executing a strong strategic pivot from ARV drugs to higher-margin CDMO, with CDMO already at 43% of revenue and Q2FY27 EBITDA surging 67% YoY to ₹680 crore. Rising FPI interest and a 128% rally from March lows reflect growing institutional conviction. Key risks include the heavy ongoing capex cycle pressuring free cash flow until post-FY27 and declining DII and retail holdings suggesting some profit-taking at current levels. The trend is firmly improving, with the peptide facility ramp-up and CDMO scaling expected to drive margin expansion toward 35% by FY29.

Headwinds 3
  • DII stake declining steadily Oct 27

    Domestic Institutional Investors reduced their holding to 11.9% in Q2FY27 from 13.7% in Q1FY27 and 14% in Q4FY26, marking a sustained decline over three quarters.

  • Public shareholding falling quarterly Oct 27

    Public shareholding (ex-FPIs and DIIs) dropped for the fourth straight quarter to 29.9% in Q2FY27 from 30.8% in Q1FY27, suggesting retail profit-booking at elevated levels.

  • Heavy ongoing capex cycle Oct 27

    Laurus Labs has already invested ₹4,300 crore with an ongoing capex exceeding ₹3,000 crore, which will pressure free cash flow until the cycle peaks post-FY27E.

Positives 6
  • Q2FY27 EBITDA surges 67% YoY Oct 19

    Q2FY27 EBITDA grew 67% year-on-year to ₹680 crore with EBITDA margin expanding 680 bps to 31.2%, significantly beating market expectations.

  • Stock rallies 128% from March Oct 19

    Shares surged 128% from their March low to ₹2,087, gaining 83% in six months and 35% in three months, vastly outperforming the BSE Sensex.

  • CDMO mix rising rapidly Oct 16

    CDMO revenue share rose from 21% in FY22 to 43% in Q1FY27, with expectations to exceed 50% by FY29 and revenue to triple to ₹7,160 crore by FY29E.

Neutral 3
  • ₹1,078 crore Krka JV investment Oct 14

    Laurus Labs invested ₹1,078 crore in Krka Pharma via a rights issue, acquiring 107.8 million shares at ₹10 face value and maintaining its 49% JV stake.

  • Q2 FY27 earnings call Oct 29 Oct 13

    Board meeting scheduled for October 29, 2026, to approve Q2 and H1 FY27 results and consider interim dividend for FY27.

  • ₹12 crore renewables investment Oct 6

    Acquired 1.21 crore shares in Kurnool Renewables for ₹12.09 crore via rights issue, maintaining its 26% stake in the subsidiary.

Quarterly Results

₹ Cr
LAURUSLABS quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,182
1,224
1,195
1,440
1,195
1,224
1,415
1,720
1,570
1,653
1,778
1,812
2,026
2,206
Expenses
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
1,299
1,388
1,456
Operating Profit
167
188
181
241
171
178
285
421
382
403
480
512
638
750
OPM %
14%
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
32%
34%
Other Income
4
2
2
19
3
5
9
59
10
27
6
12
9
—
Interest
39
42
51
50
49
53
58
56
52
40
39
40
42
44
Depreciation
91
93
98
102
106
108
106
110
117
120
121
122
124
127
PBT
41
54
35
107
18
23
131
312
224
270
327
361
481
591
Tax %
30%
27%
27%
30%
34%
22%
31%
25%
28%
28%
22%
22%
25%
26%
Net Profit
27
37
23
75
13
20
93
233
162
194
252
282
362
436
EPS (₹)
0.46
0.69
0.43
1.4
0.23
0.37
1.71
4.33
3.02
3.61
4.66
5.17
6.8
—

Sep 2026: from the results filed on 29 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
LAURUSLABS profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,327
1,778
1,905
2,056
2,292
2,832
4,814
4,936
6,041
5,041
5,554
6,813
7,270
Expenses
1,126
1,415
1,497
1,642
1,935
2,266
3,262
3,512
4,448
4,261
4,499
5,028
5,236
Operating Profit
200
362
408
414
357
565
1,552
1,424
1,592
779
1,055
1,785
2,034
OPM %
15%
20%
21%
20%
16%
20%
32%
29%
26%
15%
19%
26%
28%
Other Income
34
4
32
29
15
5
23
14
6
24
75
47
54
Interest
106
111
100
80
88
90
68
102
165
183
216
171
161
Depreciation
62
86
106
125
164
187
205
251
324
385
430
480
487
PBT
67
169
234
237
120
294
1,301
1,084
1,109
236
484
1,182
1,439
Tax %
−2%
21%
19%
29%
22%
13%
24%
23%
28%
29%
27%
25%
—
Net Profit
68
134
190
168
94
255
984
832
793
162
358
890
1,091
EPS (₹)
8.81
16.97
3.6
3.16
1.76
4.77
18.33
15.4
14.67
2.98
6.64
16.46
20.24
Div. Payout %
0%
2%
8%
9%
17%
10%
11%
13%
14%
27%
18%
12%
—

Balance Sheet

₹ Cr
LAURUSLABS balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
106
106
106
107
107
107
108
108
108
108
Reserves
640
774
1,225
1,377
1,452
1,663
2,490
3,244
3,930
4,003
4,365
5,192
Borrowings
888
1,094
842
980
1,036
1,079
1,482
1,777
2,015
2,577
2,764
2,518
Other Liabilities
345
339
481
554
737
901
1,671
1,840
1,608
1,699
2,099
2,693
Total Liabilities
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,652
3,409
3,890
4,123
4,371
CWIP
110
70
143
163
110
67
362
813
551
423
458
773
Investments
7
7
3
3
3
3
3
31
50
124
233
309
Other Assets
970
1,126
1,277
1,369
1,589
1,953
3,214
3,472
3,651
3,950
4,521
5,058
Total Assets
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511

Cash Flow

₹ Cr
LAURUSLABS cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−65
182
332
342
298
347
733
911
994
666
602
1,624
Investing
−397
−312
−289
−384
−253
−221
−941
−914
−997
−822
−680
−1,086
Financing
486
103
−54
42
−45
−128
255
30
−27
250
39
−525
Net Cash Flow
24
−27
−10
1
0
−1
47
27
−30
93
−39
13
Free Cash Flow
−447
−144
55
−49
44
125
49
34
6
−10
61
560
CFO/OP
−24
59
94
98
91
68
62
77
80
99
70
107

Ratios

LAURUSLABS financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
78
91
109
101
113
102
99
100
96
120
132
115
Inventory Days
210
176
186
201
201
234
266
293
222
277
285
317
Days Payable
102
90
96
107
144
159
199
146
94
158
141
170
Cash Conversion Cycle
186
178
199
195
170
177
166
247
224
240
276
263
Working Capital Days
0
19
3
−11
6
15
43
43
59
42
43
58
ROCE %
14%
16%
16%
14%
8%
14%
40%
26%
23%
7%
9%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Laurus Labs insights

76 extracted metrics across FY06–FY27.

Shareholding Pattern

As of Sep 2026

  • FIIs 30.84%
  • Promoters 27.47%
  • Public 20.03%
  • DIIs 11.86%
  • Others 9.81%

2.19% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Laurus Labs

What does Laurus Labs Ltd do?
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics.
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Laurus Labs Ltd trades as LAURUSLABS on the NSE and under code 540222 on the BSE.
Which sector does Laurus Labs Ltd belong to?
Laurus Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Laurus Labs Ltd?
Laurus Labs Ltd trades at a PE ratio of 114.81 as of 4 Nov 2026, on earnings per share of ₹20.24, against a book value of ₹112.17 per share.
What is the 52-week high and low of Laurus Labs Ltd?
Over the last 52 weeks Laurus Labs Ltd has traded between ₹917.95 and ₹2,441.9 as of 4 Nov 2026.
Does Laurus Labs Ltd pay dividends?
Laurus Labs Ltd has a dividend yield of 0.04%.
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Laurus Labs Ltd reported a return on equity of 18.30%. Its debt-to-equity ratio is 0.48.

Company Information

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc.

Website lauruslabs.com
CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
Employees 6,167
Listed 19 Dec 2016
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LAURUSLABS.md for Laurus Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month